The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.
An article from
Emerging biotech
The restructuring comes after an unnamed “large pharmaceutical customer” terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.
Published Aug. 24, 2026
Cellares co-founders Omar Kurdi (left) and Fabian Gerlinghaus stand next to their company's first "Cell Shuttle" manufacturing pod.
Cellares CEO seeks to 'resize' company after loss of 'large' cell therapy manufacturing customer
Cellares rebukes Bristol Myers' criticism of its cell therapy technology
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some tough…
Cellares cuts 100 jobs after Bristol Myers ends Breyanzi manufacturing deal; startup disputes claims its Cell Shuttle tech fell…
Bristol Myers exits its Cellares CAR-T manufacturing deal after the Cell Shuttle falls short, prompting a reorg at Cellares.
After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have opened…
With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies have…
Australian biopharma Clinuvel Pharmaceuticals is
